Key result
PVA-cis-ADOX demonstrated significantly higher cytotoxicity than PVA-trans-ADOX in J774.1 cells, with an IC50 of 18 μg eq DOX/ml compared to 0.48 μg/ml for free doxorubicin.
PVA-cis-ADOX conjugates release doxorubicin more rapidly in acidic conditions and exhibit greater in vitro cytotoxicity compared to trans-isomers, suggesting potential as a targeted macromolecular prodrug.
Answers are grounded in this paper and cite their sources.
PVA-cis-ADOX merits further preclinical testing as an acid-labile prodrug; leaves open whether isomer configuration improves antitumor efficacy in vivo.
Aconityl-doxorubicin (ADOX) was synthesized by the modified method of Shen and Ryser. Two isomers of cis-ADOX (cis-configuration) and trans-ADOX (trans-configuration) were generated in the reaction of DOX and cis-aconitic anhydride. These products were separated completely by using HPLC and analyzed by TOF-MS spectroscopy and (1)H- and (13)C-NMR experiments. The yields of cis-ADOX and trans-ADOX were 36.3 and 44.8%, respectively. The free gamma-carboxylic group of ADOX molecule was coupled to poly(vinyl alcohol) (PVA) via ethylenediamine spacer, resulting the macromolecular conjugates of PVA-cis-ADOX and PVA-trans-ADOX, respectively. The DOX content of the conjugates estimated by the hydrolysis method detected the aglycone of DOX which can be estimated as the PVA-bound DOX selectively was 4.4 w/w% which was similar to 4.6 w/w% by the ordinary UV method. Both PVA-cis-ADOX and PVA-trans-ADOX were very stable at neutral pH, but the release of DOX was increased markedly under acidic conditions. Half-life of the release of DOX from PVA-cis-ADOX at pH 5.0 was 3 h which was 4.7-fold shorter than that from PVA-trans-ADOX (14 h). The cytotoxicities of PVA-cis-ADOX and PVA-trans-ADOX were evaluated by using J774.1 cells employing a [(3)H]uridine incorporation assay as a measure of RNA synthesis. A significant difference in antitumor activity between PVA-cis-ADOX and PVA-trans-ADOX was observed where the former was much active than the later. It was suggested that the conjugate enters the cells and reaches the lysosomal/endosomal compartment, and that the aconityl spacer releases DOX from the conjugate in the acidic compartment of lysosomes/endosomes due to the participation of a free carboxylic group.
No takes yet. Share an insight, caveat, or question.
Kakinoki et al. (2008) studied Cancer (in vitro models). PVA-cis-ADOX and PVA-trans-ADOX vs. Free doxorubicin (DOX) was evaluated on In vitro cytotoxicity (IC50) in J774.1 cells. PVA-cis-ADOX demonstrated significantly higher cytotoxicity than PVA-trans-ADOX in J774.1 cells, with an IC50 of 18 μg eq DOX/ml compared to 0.48 μg/ml for free doxorubicin.
Synapse has enriched 10 related papers. Consider them for comparative context: